Magdalena Biosciences to Present at Annual Neuroscience Innovation Forum

Magdalena Biosciences, a joint venture between Jaguar Health (NASDAQ: JAGX) and Filament Health (NEO: FH), is set to present at the 8th Annual Neuroscience Innovation Forum (NIF) on January 12, 2025. The event, organized by Sachs Associates, will take place at the Marines’ Memorial Club in San Francisco, a day before the JP Morgan Healthcare Conference and the Virtual Week from January 21-23.

Magdalena Biosciences, formed in 2023, aims to develop novel, natural prescription medicines derived from plants for mental health indications. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications. Magdalena's mission is to de-risk early and increase the probability of future FDA-approved botanical drugs by leveraging centuries of medicinal use.



Magdalena's first Investigational New Drug (IND) application, MB2500, is ready to file in 2025 for improvement in executive function in ADHD or cognitive deficit in schizophrenia. The drug candidate has shown statistically significant efficacy in animal models of disease, with improvement in cognition equivalent or better than donepezil, the drug most commonly used to treat Alzheimer’s disease. PET scan data show an increase in neuronal activity in the prefrontal cortex with statistically significant increases in connectivity among brain areas, leading to potential neuronal remodeling relevant to various psychiatric disorders.

The NIF forum focuses on the latest developments across key areas of neuroscience, attracting record investor interest and deal flow. The main program for the 8th Annual NIF will feature more than 8 hours of high-level keynotes and panel discussions addressing important advances in therapeutic, neurotech, and diagnostics fields.

Magdalena Biosciences' presentation at the NIF forum is an opportunity for the company to showcase its unique botanical drug development approach and pipeline of drug candidates. The event provides a platform for the company to connect with potential investors, partners, and industry experts, further advancing its mission to develop safe and efficacious next-generation psychoactive FDA-approved drugs for daily use.

Magdalena Biosciences' focus on ADHD and cognitive deficit in schizophrenia addresses significant unmet medical needs. ADHD affects approximately 50-65% of individuals into adulthood, with 20-50% of adult patients being non-responders or intolerant to current therapeutics. Schizophrenia, a chronic, disabling mental illness, affects about 1% of the U.S. population, with a projected global market of $13.41 billion by 2032. The cognitive deficit in schizophrenia, a huge unmet medical need, appears a decade before psychotic symptoms but has no approved drug treatment.

Magdalena Biosciences' partnership with One Small Planet, a vital capital group focused on regenerative technologies, supports the company's mission and financial sustainability. The partnership provides initial funding of US$1,000,000, with funds payable in quarterly installments in 2023 based on defined milestones. This collaboration enables Magdalena to extend the botanical drug development capabilities of Jaguar and Filament, aiming to develop pharmaceutical-grade, standardized drug candidates for mental health disorders.

In conclusion, Magdalena Biosciences' presentation at the 8th Annual Neuroscience Innovation Forum is an important milestone for the company, providing an opportunity to showcase its unique botanical drug development approach and pipeline of drug candidates. The event offers a platform for the company to connect with potential investors, partners, and industry experts, further advancing its mission to develop safe and efficacious next-generation psychoactive FDA-approved drugs for mental health indications.